Meeting
2013 ASCO Annual Meeting
Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors.
Authors
Gerald Steven Falchook
Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX
Gerald Steven Falchook , Jayesh Desai , Ian M. Leitch , Jonathan Wade Goldman , Jennifer J. Wheler , Siqing Fu , Razelle Kurzrock , Megan Baldwin , Lee S. Rosen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Angiogenesis
Clinical Trial Registration Number
NCT01514123
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS2619)
DOI
10.1200/jco.2013.31.15_suppl.tps2619
Abstract #
TPS2619
Poster Bd #
11G
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors.
First Author: Gerald Steven Falchook
Poster
2014 ASCO Annual Meeting
A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies.
First Author: Kyriakos P. Papadopoulos
Poster
2024 ASCO Annual Meeting
First-in-human study of ZGGS18, a dual specific antibody targeting VEGF and TGF-β, as monotherapy in patients with advanced solid tumors.
First Author: Chuan Hua Zhao
Poster
2022 ASCO Annual Meeting
First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.
First Author: Nong Xu